Grin Therapeutics (Series D)
Funding Details
- Awarder
- Inbox
- Date Award
- May 28, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $140,000,000
Company Info
- Traction
- The company is advancing Radiprodil in multiple rare genetic epilepsies and neurodevelopmental disorders, with ongoing clinical trials.
- Organizations Involved
- Angelini Pharma, Blackstone Life Sciences
- Founders
- Bruce Leuchter, MD
- Company Description
- Grin Therapeutics, Inc. is a leader in the development of therapies to treat serious neurodevelopmental disorders, advancing Radiprodil, a targeted, selective, and potent negative allosteric modulator of the GluN2B subunit of the NMDA receptor.
- Market
- Neurodevelopmental disorders
- Location
- New York City, New York, USA
- Coinvestors
- Angelini Pharma, Blackstone Life Sciences